Sexton Biotechnologies to pursue commercialization of cell and gene therapy bioproduction tools

Sexton Biotechnologies marks the first spin out from Cook Regentec’s technology incubator and accelerator

Indianapolis, Ind. – Today Cook Regentec, a technology incubator and accelerator, announced the formation and spin out of an independent biotechnology company, Sexton Biotechnologies. In addition to ongoing research and product development, the newly formed company will expand and scale commercialization of cell and gene therapy bioproduction tools from its portfolio of container closure and media supplementation platforms. Sexton Biotechnologies will be located in the 16 Tech innovation district in Indianapolis, Indiana.

The newly formed Sexton Biotechnologies is comprised of a 16-person team from Cook Regentec who developed, incubated and commercialized the technologies since 2015. Sean Werner, an executive leader of the team, has been named as President and CEO of the new company. Sexton Biotechnologies is the first company incubated by Cook Regentec to graduate to independence and secure outside investment capital. Sexton Biotechnologies will lease production and office space inside Cook Regentec’s facility located in the 16 Tech innovation district through 2024.

The investment group providing growth capital for Sexton Biotechnologies includes BioLife Solutions (BLFS: NASDAQ) a leading developer and supplier of bioproduction tools, Casdin Capital, Biocrossroads and Cook Regentec. Sexton Biotechnologies will continue commercialization and further development of their CellSeal platform and human platelet lysate(hPL)-based growth supplements; Stemulate, nLiven PR, and the soon to be released T-cell specific growth supplement, T-Liven PR.

Sexton’s CellSeal platform is based around the idea of providing the benefits of a rigid, cryo-compatible closed vial with the flexibility to fit into cell and gene therapy processing methods. Sexton plans to continue building on this platform to bring novel solutions to cell and gene therapy manufacturing operations allowing flexible integration to accelerate process development. The line of hPL-based supplements includes a standard pooled platelet lysate, an irradiated pooled platelet lysate (PR), and a T-cell activity verified PR product.

“The launch and funding of Sexton Biotechnologies is exactly the kind of activity we’ve all been working toward for Indiana’s life sciences ecosystem. When ideas are born in our great universities, translated into products by entrepreneurial companies like Cook, and then gain the commercial momentum to attract top notch strategic capital partners from Indiana and outside the state, it’s an early indicator that our vision for life science innovation in Indiana is starting to work,” said Rob Lyles, president of Cook Regentec. “We’re excited that BioLife Solutions and Casdin Capital looking at Indiana and decided to invest in Sexton to help scale their potential. Being able to create and grow in a place like 16 tech and have the support and capital of partners like BioCrossroads is a proof point to the booming life sciences center we have within the state.”

Cook Regentec is currently incubating two other companies unrelated to Sexton Biotechnologies in its portfolio; a veterinary cell therapy company and a medical device company for delivery of advanced therapeutics. Sexton Biotechnologies will be fully independent of Cook Regentec after the closing scheduled for October 1, 2019. For more information about Sexton Biotechnologies, please visit their website or reach out to the contact below.


“The opportunity to work closely with partners of such deep expertise in the cell and gene therapy industry will drive new focus to continue our growth. We’re excited for the opportunity to work with BioLife Solutions to leverage their sales and marketing resources as we work to expand our customer base. This new round of investment will give us additional resources to further develop and support our unique products.”

– Sean Werner


Sexton Biotechnologies is a revenue stage, biotechnology company focused on the development and sales of bioproduction tools for cell and gene therapy founded in 2019 as a spin out of Cook Regentec, a business and medical technology incubator located in Indianapolis, IN. Sexton develops purpose-built CGT tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points, and labor costs. Sexton’s portfolio includes the CellSeal platform of cryo-storage tools and fill/finish systems and human platelet lysate growth supplements. More information at

Sexton Biotechnologies
Sean Werner
Cook Regentec is an Indianapolis, Indiana-based company that develops research and clinical tools to advance regenerative medicine therapies from the lab to the patient. Its portfolio of innovations includes enabling technologies and tools for cell-based therapies and cGMP bioprocessing. From concept to commercialization, Cook Regentec’s product lines cover expansion, packaging, storing, thawing, delivering, and processing.

Media Contact: Laura Miller and Laura.miller@lmcommunications